Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients

This comparative effectiveness study of immunocompromised patients and healthy controls in Switzerland examines differences in the magnitude and durability of neutralizing antibody responses against the original SARS-CoV-2 and several variants of concern according to the mRNA-1273 and BNT162b2 vaccines.

Lascia un commento